Could a simple drug stop confusion after brain surgery?
NCT ID NCT07398066
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a medicine called dexmedetomidine can reduce pain and prevent confusion (delirium) in adults after brain surgery. Sixty people having planned brain tumor removal will receive either the drug or a placebo during surgery. The goal is to see if it lowers pain scores and the need for strong painkillers, while avoiding breathing problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All adult (American Society of Anaesthesiologists (ASA 1-2) who \>18 years old and \<65 years old undergoing elective craniotomy Exclusion Criteria: * Patients who are ASA 3-5 or BMI \<18/ \>40 or allergic to dexmedetomidine will be excluded. Patients with high-grade heart block or uncontrolled bradyarrhythmia will also be excluded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Treatment strategies for tumor in sellar region with unruptured intracranial aneurysms in the chinese population
- Brain surgery safety: live signal monitoring may shield speech, movement, and sight
- Can a simple dye help surgeons see brain tumors in real time?
- Could blocking a Tumor's blood supply shrink brain meningiomas?
- New platform trial takes on NF2 tumors with multiple drug strategies
- Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?